- Home
- BOLD vs IGC Comparison
BOLD vs IGC Comparison
Compare BOLD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | IGC |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 28.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOLD | IGC |
|---|---|---|
| Price | $1.22 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.00 | ★ $4.13 |
| AVG Volume (30 Days) | 125.9K | ★ 465.2K |
| Earning Date | 11-05-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.25 |
| 52 Week High | $2.54 | $0.50 |
Technical Indicators
Market Signals| Indicator | BOLD | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 46.13 |
| Support Level | $1.19 | $0.29 |
| Resistance Level | $1.31 | $0.31 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 12.50 | 37.71 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.